<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Siraj, Elias S.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Insulin Dose Not Linked to Cardiovascular Mortality in the ACCORD Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Previously published results from the Action to Control Cardiovascular Risk in Diabetes study [ACCORD; ACCORD Study Group. N Engl J Med 2008] showed an increased risk of all-cause and cardiovascular (CV) mortality in the intensive control group (HbA1C target, &lt;6.0%) compared with the less intensive group (HbA1C target, 7.0% to 7.9%). Several post hoc analyses did not find a conclusive link between the ACCORD results and factors such as hypoglycemia, low HbA1C, the rapid decline in HbA1C during the first year of the study, weight gain, and specific medication use.</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>